



MIMICS^{3D} Three-Year Results

Summary

A prospective observational registry evaluating the BioMimics 3D Vascular Stent System in a real-world clinical population with a dedicated subgroup analysis of device performance as a complementary treatment in procedures involving drugcoated balloons. MIMICS-3D enrolled 507 patients across 23 clinical sites in Europe.

24% of subjects enrolled in MIMICS-3D had Critical Limb Threatening Ischemia (CLTI)

Baseline Patien	N=507 Subjects				
Age	Mean years ± SD (N)	70 ± 10 (507)			
Gender	% Male	66% (332/507)			
Risk Factors	Diabetes Mellitus	37% (187/507)			
RISK Factors	Smoker Current	38% (191/507)			
	0	0.4% (2/504)			
Rutherford category	1	1% (6/504)			
	2	17% (86/504)			
	3	57% (289/504)			
categoty	4	8% (38/504)			
	5	14% (72/504)			
	6	2% (11/504)			
Ankle Brachial Index	$Mean \pm SD(N)$	0.6 ± 0.3 (417)			

38% of lesions had moderate to severe calcification

Baseline Lesion Cl	N=507 Subjects (518 lesions)			
Reference Vessel Diameter	Mean ± SD (N)	5.5mm ± 0.7		
Lesion Location	Mid +/- Distal Third	86% (445/518)		
	Prox. Pop	29% (150/518)		
Diameter Stenosis	$Mean \pm SD$	95% ± 8 (518)		
Occlusions	Total	57% (294/518)		
Lesion Length	$Mean \pm SD$	126mm ± 91		
	Grade 0	18% (91/516)		
	Grade 1	30% (152/516)		
Calcification	Grade 2	24% (126/516)		
	Grade 3	15% (76/516)		
	Grade 4	14% (71/516)		

Study Principal Investigator:

Michael Lichtenberg MD, Arnsberg, Germany

Enrolment complete: N=507

Clinical Sites: 23 Pan European

Follow Up: 3 Years


Primary Endpoints:


Safety – Composite of major adverse events (MAE), death, major amputation performed or clinically-driven target lesion revascularisation (CDTLR) through 30 days.

Effectiveness – Freedom from CDTLR through 12 months.

KM Freedom from CDTLR at 3 years

Data from a challenging real-world population continue to demonstrate the therapeutic value of swirling flow in the BioMimics 3D stent.





Conclusions

MIMICS-3D data contribute real-world experience to the evolving database supporting the therapeutic value of swirling flow in the BioMimics 3D stent.

- More challenging population than typically enrolled in registry studies: • 24% CLTI; longer, more complex lesions; 50% with DCB.
- 78% Freedom from CDTLR at 3 Years.
- Rate of CDTLR was independent of concomitant DCB use, lesion calcification and stent length.

MIMICS Clinical Programme investigations into the performance of the BioMimics 3D Vascular Stent system support the hypothesis that imparting non-planar curvature to the femoropopliteal artery to promote swirling blood flow and increase wall shear stress, results in clinical outcomes that are comparable to those of drug-eluting devices.¹

The MIMICS Clinical Programme: An evolving database of the safety and effectiveness of the BioMimics 3D Vascular Stent System.

Gathering clinical evidence from a "real world" patient population from single de novo to complex, long and severely calcified lesions.

1750+ patients and growing

MIMICS FIH	MIMIC	S RCT	MIMICS 2 N = 271 43 sites USA/Japan/Germany		MIMICS ^{3D} N = 507 23 sites Pan European		MIMICS ^{3D} USA N = c. 500 c. 40 sites USA			MIMICS et seq	
N = 10 1 site Germany	N = 50 8 sites Germany	>							>	N = c. 400 Multiple sites Europe	
• First in Human • FU - 1 year • Completed	 Randomised controlled trial FU - 2 years Completed 		 IDE Registry FU - 3 years Completed 		 Prospective Registry FU - 3 years Completed 		 Prospective Registry FU - 3 years Enrolment ongoing 		 Physician initiated prospective and retrospective registries Enrolment ongoing 		
MIMICS RCT		MIMICS 2		Γ	MIMICS ^{3D}			MIMICS	3D	USA	
A randomised study comparing safety and effectiveness of the		A multicer	multicentre, international JSA, Japan and Germany) IDE		A prospective observational registry evaluating the			A prospective, multicentre observational study evaluating			
		(USA, Japa									
BioMimics 3D Vascular Stent		study. At 3 years follow-up			BioMimics 3D Vascular			the safety, effectiveness and			
System to a straight stent		BioMimics 3D demonstrated			Stent System in a real-world			device performance of the			
control. Freedom from loss of		continuing benefit with CDTLR			clinical population with a			BioMimics 3D Vascular Stent			
		showing comparable outcomes			dedicated subgroup analysis			System within a real-world			
			DES/DCB. Core Lab X-ray		of device performance as a			clinical population of patients			
		5 5	ing review confirmed 0%		complementary treatment in			undergoing femoropopliteal			
5			acture in any MIMICS-2		procedures involving drug-		0	intervention. MIMICS-3D USA			
(72% vs 55%). There w											
stent fractures at 2 yea			· ·	enrolled 507 patients across					up to 40 sites across		
	ne	0	g patient population.		23 clinical sites in Eur	op	e.	the Unit	ed	States.	
patients treated with the BioMimics 3D stent. ²		then in DE	S/DCB pivotal trials. ^{3.4}								

1. Data on file at Veryan Medical

2. Zeller T et al; Circ Cardiovasc Interv. 2016;9

3. Kenneth Rosenfield et al :N Engl J Med 2015;373:145-53. DOI: 10.1056/NEJMoa1406235

4. Michael D. Dake et al : Circ Cardiovasc Interv. 2011;4:495-504

The BioMimics 3D Vascular Stent System has CE Mark approval.

BioMimics 3D and Swirling Flow are registered trademarks of Veryan Medical Ltd. ©2022 Veryan Medical Ltd.

Indications, contraindications, warnings and Instructions for Use can be found in the product labelling supplied with each device. All cited trademarks are the property of their respective owners.

For additional information please contact your local representative.

GERMANY T +49 3222 999 0027 E veryanmedical@healthlinkeurope.com W veryanmed.com

ALL OTHER EUROPEAN COUNTRIES

T +31 (0)73 303 5510 E veryanmedical@healthlinkeurope.com W veryanmed.com



